Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Authorised, recruitment pending
Participants planned
15
Countries
1
Sites
1
Knee osteoarthritis
Key facts
- Sponsor
- Scarcell Therapeutics
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Musculoskeletal Diseases [C05]
- Decision date (initial)
- 2026-05-26
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Knee osteoarthritis
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 21.1 | LLT | 10023476 | Knee osteoarthritis | 10028395 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Scarcell Therapeutics
- Sponsor organisation
- Scarcell Therapeutics
- Address
- 101 Rue De Sevres
- City
- Paris
- Postcode
- 75006
- Country
- France
Scientific contact point
- Organisation
- Scarcell Therapeutics
- Contact name
- Chief Medical Officer
Public contact point
- Organisation
- Scarcell Therapeutics
- Contact name
- Chief Executive Officer
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Denmark | Authorised, recruitment pending | 10 | 1 |
| Rest of world
United Kingdom
|
— | 5 | — |
Investigational sites
Dantrials ApS
Department of Clinical Pharmacology, Nielsine Nielsens Vej 6b, 2400, Copenhagen Nv
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-03-20 | Denmark | Acceptable with conditions 2026-05-22
|
2026-05-26 |